- This topic is empty.
-
Posts
-
Understanding 2-(Chloromethyl)-4-Methylquinazoline in Diabetes Intermediate Sourcing
2-(Chloromethyl)-4-methylquinazoline, identified by CAS number 109113-72-6, is listed within the Anti-Diabetic Products category of Shandong Tianming Pharmaceutical Group, a company operating under the brand name Tianming Pharmaceutical. This compound sits among a broader set of 36 anti-diabetic intermediates and APIs offered by the group, which also includes building blocks supporting Alogliptin Benzoate, Linagliptin, Dapagliflozin, Empagliflozin, and Orforglipron full-chain intermediates. For procurement and R&D teams evaluating where to source this specific quinazoline-based intermediate, understanding its synthetic role and the supplier capabilities behind it is a useful starting point before making a sourcing decision.
Its Position in the Linagliptin Synthetic Route
Within the product sequence disclosed by Tianming Pharmaceutical’s Anti-Diabetic Products line, 2-Chloromethyl-4-methylquinazoline appears alongside a series of related intermediates: 3-Methylxanthine, 8-Bromo-3-methylxanthine, and 8-Bromo-7-(2-butynyl)-3-methylxanthine. These xanthine-based intermediates are positioned adjacent to 2-Chloromethyl-4-methylquinazoline and to 8-Bromo-7-(2-butyn-1-yl)-3,7-dihydro-3-methyl-1-[(4-methyl-2-quinazolinyl)methyl]-1H-purine-2,6-dione, which in turn connects to tert-Butoxycarbonyl Linagliptin and ultimately Linagliptin. The presence of the “4-methyl-2-quinazolinyl” methyl group in that purine-dione intermediate indicates that 2-Chloromethyl-4-methylquinazoline functions as the quinazoline-methyl building block introduced during this stage of the route. Buyers purchasing this intermediate are typically doing so because it feeds into this xanthine-to-Linagliptin pathway, making route consistency and supplier familiarity with the full chain relevant factors in a sourcing decision.
Key Considerations When Selecting a Supplier
Verify Identity and Structural Documentation
Because intermediates in multi-step syntheses must match downstream reaction requirements precisely, confirming the CAS number (109113-72-6) against supplier documentation is a baseline step. Tianming Pharmaceutical states that complete COA and structural confirmation documentation is available for all products in its catalog, which allows buyers to cross-check identity before committing to a batch.
Assess Batch Traceability and Quality Systems
Industry pain points commonly cited include inconsistent batch quality that interrupts downstream production. Tianming Pharmaceutical’s data capabilities section describes full batch traceability across raw material receipt, reaction parameters, purification processes, and testing data, with all records archived for complete chain-of-custody traceability. The company also operates under a GMP-compliant quality assurance system and holds ISO9001 Quality Management System Certification at its Shandong Sihuan Pharmaceutical Co., Ltd. entity (2025) and Guangxi Tianming Pharmaceutical Co., Ltd. entity (2024).
Evaluate Production Scale and Capacity
Fragmented sourcing across multiple suppliers is another pain point noted in the company’s background materials, often driven by suppliers lacking capacity to scale beyond lab-batch quantities. Tianming Pharmaceutical operates three coordinated production bases with over 160 reactor vessels and an annual production capacity in the hundreds of tons, supporting supply from gram-level to ton-level across laboratory, pilot, and commercial production stages.
Confirm Independent Process Development Capability
Matching process parameters for niche intermediate categories is cited as an industry challenge. Tianming Pharmaceutical directs more than 10% of annual revenue to R&D, compared with an industry average cited at around 5%, and maintains two R&D centers in Jinan and Nanjing with over 6,000 square meters of laboratory space and more than 100 R&D personnel. The company also allocates an additional 1% of revenue specifically to management system iteration, supporting consistency across its IPD integrated product development process.
Review Delivery Timeline and Service Support
For buyers with time-sensitive R&D or regulatory filing schedules, delivery terms matter. Tianming Pharmaceutical states that in-stock orders are delivered within 7–15 working days following order confirmation, quality review, packaging, and shipping, while made-to-order lead times depend on synthesis complexity, workshop scheduling, and raw material availability, with expedited scheduling available for urgent projects. Service assurance includes a 1-on-1 account manager plus technical engineer support model, with routine technical questions addressed within 2 hours and complex issues resolved via a written report within 24 hours.
Check Regulatory Filing Support
Where this intermediate is used in regulated drug development, documentation supporting DMF and CEP filings is relevant. Tianming Pharmaceutical notes that its product documentation includes COA, MOA methodology, impurity profile studies, and stability data intended to support such global regulatory filings.
Tianming Pharmaceutical Group’s Position in the Anti-Diabetic Intermediate Chain
Shandong Tianming Pharmaceutical Group traces its origins to Shandong Sihuan Pharmaceutical Co., Ltd., founded in 2010, with the group formally established in 2020. The company has been recognized as a National High-Tech Enterprise across its Shandong Sihuan (2024), Shandong Tianming Pharmaceutical Technology (2025), and Guangxi Tianming (2023) entities. Notably, the group’s Dezhou operations received the Dezhou Science and Technology Progress Third Prize in 2020 specifically for a DPP-4 inhibitor class diabetes drug preparation method, a recognition directly tied to the therapeutic category that 2-Chloromethyl-4-methylquinazoline serves as a building block within. The group also received the Dezhou Science and Technology Progress Second Prize in 2022 for an anti-tumor drug preparation method, indicating recognized technical work spanning multiple therapeutic areas beyond diabetes.
Operationally, the group’s CRM, ERP, and BPM digital management systems are described as supporting order management, inventory, production scheduling, and customer service coordination, which the company positions as enabling rapid domestic order confirmation and full international logistics chain services across its international footprint, which covers 30+ countries and regions including South Asia, Southeast Asia, the Middle East, Central and South America, and Africa.
A Practical Checklist for Buyers
Before finalizing a sourcing decision for 2-Chloromethyl-4-methylquinazoline or related DPP-4 inhibitor intermediates, buyers may reasonably ask a prospective supplier to confirm: CAS number and structural documentation accuracy; availability of COA, impurity profile, and stability data; GMP compliance status and batch traceability records; production scale sufficient for the intended development stage (laboratory, pilot, or commercial); typical in-stock versus made-to-order lead times; and technical support response commitments for both routine and complex questions.
Conclusion
Selecting a supplier for 2-(chloromethyl)-4-methylquinazoline involves more than confirming a CAS number match. Because the compound functions within a defined synthetic sequence toward Linagliptin, buyers benefit from working with a supplier that demonstrates documented quality systems, scalable production infrastructure, and recognized technical history in the DPP-4 inhibitor category. Shandong Tianming Pharmaceutical Group’s disclosed capabilities across its anti-diabetic product line, production bases, and quality documentation practices provide a reference framework that buyers can use to evaluate this and comparable intermediate sourcing decisions.
Tianming Pharmaceutical Group
- You must be logged in to reply to this topic.